Comment from National Association of Boards of Pharmacy

Summary: The National Association of Boards of Pharmacy (NABP) states that it neither supports nor opposes the inclusion of the peptides on the 503A Bulks List, but expresses significant concern regarding the lack of regulatory infrastructure to oversee large-scale compounding. They argue that the current 503A framework is ill-equipped for high-volume production and recommend that the FDA establish information-sharing agreements, traceability measures, and adverse event reporting mechanisms before finalizing the rule.